Ionis Pharmaceuticals (IONS) News Today $35.63 +0.04 (+0.11%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Ionis Pharmaceuticals: Promising Growth From Tryngolza ApprovalDecember 23 at 7:41 AM | seekingalpha.comIonis Pharmaceuticals' (IONS) "Outperform" Rating Reiterated at William BlairDecember 23 at 2:57 AM | americanbankingnews.comFY2028 Earnings Estimate for IONS Issued By William BlairIonis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) - Equities research analysts at William Blair reduced their FY2028 earnings per share (EPS) estimates for Ionis Pharmaceuticals in a research note issued to investors on Friday, December 20th. William Blair analyst M. Minter now anticipatesDecember 23 at 2:23 AM | marketbeat.comIonis Pharmaceuticals (IONS) Announces FDA Approval of Tryngolza™ for Treatment of Familial Chylomicronemia SyndromeDecember 22 at 4:13 AM | americanbankingnews.comIonis stock rises following FDA approval of TRYNGOLZADecember 21 at 12:40 PM | ca.investing.comIonis gets FDA approval for TryngolzaDecember 21 at 12:15 AM | msn.comThe Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 6 ExpertsDecember 21 at 12:15 AM | benzinga.comIonis Pharmaceuticals (NASDAQ:IONS) Given "Buy" Rating at Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and set a $60.00 price objective on shares of Ionis Pharmaceuticals in a research report on Friday.December 20 at 8:31 AM | marketbeat.comIonis Pharmaceuticals (NASDAQ:IONS) Receives "Outperform" Rating from William BlairWilliam Blair reiterated an "outperform" rating on shares of Ionis Pharmaceuticals in a research note on Friday.December 20 at 8:07 AM | marketbeat.comTRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to dietDecember 19, 2024 | prnewswire.comUS FDA approves Ionis Pharma's genetic disorder drugDecember 19, 2024 | reuters.comGeode Capital Management LLC Has $106.92 Million Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Geode Capital Management LLC increased its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 7.4% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 2,668,358 shares of the company's stock after purchasing an additional 183,814 sharDecember 19, 2024 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Sees Significant Decline in Short InterestDecember 18, 2024 | americanbankingnews.comBrokerages Set Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Price Target at $60.65December 17, 2024 | americanbankingnews.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Short Interest Down 5.4% in NovemberIonis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) was the target of a significant decrease in short interest in November. As of November 30th, there was short interest totalling 10,450,000 shares, a decrease of 5.4% from the November 15th total of 11,050,000 shares. Currently, 7.2% of the shares of the stock are short sold. Based on an average daily volume of 1,700,000 shares, the short-interest ratio is presently 6.1 days.December 17, 2024 | marketbeat.comY Intercept Hong Kong Ltd Takes $807,000 Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Y Intercept Hong Kong Ltd acquired a new position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 20,141 shares of the company's stoDecember 14, 2024 | marketbeat.comStifel Financial Corp Sells 33,635 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Stifel Financial Corp lowered its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 15.6% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 182,505 shares of the company's stock after selling 33,635 shares during theDecember 14, 2024 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Consensus Rating of "Moderate Buy" by BrokeragesShares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) have earned an average recommendation of "Moderate Buy" from the nineteen analysts that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, five have given a hold recoDecember 14, 2024 | marketbeat.comXTX Topco Ltd Makes New Investment in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)XTX Topco Ltd bought a new position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 16,805 shares of the company's stock, valued at approximately $673,000. SevDecember 13, 2024 | marketbeat.comIonis Pharmaceuticals (IONS) Gets a Buy from OppenheimerDecember 10, 2024 | markets.businessinsider.comGroupama Asset Managment Raises Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Groupama Asset Managment lifted its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 4.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 916,060 shares of the comDecember 10, 2024 | marketbeat.comIonis Pharmaceuticals (IONS) Down 4.5% Since Last Earnings Report: Can It Rebound?December 7, 2024 | uk.finance.yahoo.comIonis Pharmaceuticals management to meet with OppenheimerDecember 6, 2024 | markets.businessinsider.comJacobs Levy Equity Management Inc. Purchases 77,909 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Jacobs Levy Equity Management Inc. raised its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 13.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 650,779 shares of the comDecember 4, 2024 | marketbeat.comErste Asset Management GmbH Makes New Investment in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Erste Asset Management GmbH acquired a new position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 51,300 shares of the company's stock, valued at approximaDecember 4, 2024 | marketbeat.comThe Manufacturers Life Insurance Company Buys 34,097 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)The Manufacturers Life Insurance Company raised its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 12.4% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 308,947 shares of the company's stock after acquiring anDecember 3, 2024 | marketbeat.comIonis added to Analyst Current Favorites list at Raymond JamesDecember 2, 2024 | markets.businessinsider.com223,470 Shares in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Purchased by Baker BROS. Advisors LPBaker BROS. Advisors LP acquired a new stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 223,470 shares of the company's sDecember 2, 2024 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Position Reduced by Bellevue Group AGBellevue Group AG reduced its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 4.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,874,400 shares of the company's stock afterDecember 1, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Purchases 114,914 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Charles Schwab Investment Management Inc. lifted its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 8.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,443,020 shares of the company's stocNovember 30, 2024 | marketbeat.comHBK Investments L P Makes New Investment in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)HBK Investments L P bought a new position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 60,000 shares of the company's stock, valued at approximately $2,4November 29, 2024 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by Connor Clark & Lunn Investment Management Ltd.Connor Clark & Lunn Investment Management Ltd. decreased its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 59.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 17,741 shNovember 29, 2024 | marketbeat.comAnalysts Conflicted on These Healthcare Names: Ionis Pharmaceuticals (IONS) and GoodRx Holdings (GDRX)November 29, 2024 | markets.businessinsider.comAlgert Global LLC Sells 29,920 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Algert Global LLC decreased its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 39.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 45,430 shares of the company's stoNovember 28, 2024 | marketbeat.comGreat Point Partners LLC Cuts Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Great Point Partners LLC trimmed its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 22.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 255,000 shares of the company's stockNovember 27, 2024 | marketbeat.comLandscape Capital Management L.L.C. Invests $1.02 Million in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Landscape Capital Management L.L.C. bought a new stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 25,435 shares of the company's stock, valued at apprNovember 23, 2024 | marketbeat.comWhy Is Ionis Pharmaceuticals, Inc. (IONS) Among the Worst Performing Biotech Stocks in 2024?November 21, 2024 | finance.yahoo.comIonis Pharmaceuticals, Inc. (IONS): Among the Best Genomics Stocks to Buy Right NowNovember 20, 2024 | msn.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Average Recommendation of "Moderate Buy" by BrokeragesShares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the nineteen brokerages that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, five have assNovember 19, 2024 | marketbeat.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Sees Large Increase in Short InterestIonis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) saw a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 10,740,000 shares, a growth of 8.8% from the October 15th total of 9,870,000 shares. Based on an average daily volume of 1,540,000 shares, the short-interest ratio is currently 7.0 days. Currently, 7.4% of the shares of the stock are short sold.November 18, 2024 | marketbeat.comIonis Pharmaceuticals price target lowered to $62 from $65 at Piper SandlerNovember 15, 2024 | markets.businessinsider.comIonis Pharmaceuticals (NASDAQ:IONS) Hits New 12-Month Low on Insider SellingIonis Pharmaceuticals (NASDAQ:IONS) Sets New 12-Month Low After Insider SellingNovember 15, 2024 | marketbeat.comEric Swayze Sells 1,194 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) StockNovember 15, 2024 | insidertrades.comPiper Sandler Has Lowered Expectations for Ionis Pharmaceuticals (NASDAQ:IONS) Stock PricePiper Sandler lowered their target price on shares of Ionis Pharmaceuticals from $65.00 to $62.00 and set an "overweight" rating for the company in a report on Thursday.November 14, 2024 | marketbeat.comBaillie Gifford & Co. Cuts Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)Baillie Gifford & Co. lessened its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 84.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 39,581 shares of the company's stock afterNovember 14, 2024 | marketbeat.comIonis Pharmaceuticals (NASDAQ:IONS) Downgraded by StockNews.com to "Sell"StockNews.com downgraded Ionis Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Tuesday.November 12, 2024 | marketbeat.comWhat is Leerink Partnrs' Forecast for IONS FY2024 Earnings?Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) - Research analysts at Leerink Partnrs lifted their FY2024 earnings per share (EPS) estimates for shares of Ionis Pharmaceuticals in a research report issued to clients and investors on Wednesday, November 6th. Leerink Partnrs analyst M. ForNovember 11, 2024 | marketbeat.comLeerink Partnrs Analysts Reduce Earnings Estimates for IONSIonis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) - Equities researchers at Leerink Partnrs cut their FY2028 earnings per share (EPS) estimates for Ionis Pharmaceuticals in a research note issued to investors on Wednesday, November 6th. Leerink Partnrs analyst M. Foroohar now forecasts thatNovember 8, 2024 | marketbeat.comARK Investment Management LLC Boosts Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)ARK Investment Management LLC raised its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 1.7% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,384,269 shares of the company's sNovember 8, 2024 | marketbeat.comIonis Pharmaceuticals (IONS) Gets a Hold from BarclaysNovember 8, 2024 | markets.businessinsider.com Get Ionis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter. Email Address URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight. >> Register for the Workshop Now IONS Media Mentions By Week IONS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IONS News Sentiment▼0.700.60▲Average Medical News Sentiment IONS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IONS Articles This Week▼197▲IONS Articles Average Week Get Ionis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BIIB News Today UTHR News Today NBIX News Today INCY News Today BMRN News Today EXAS News Today EXEL News Today RGEN News Today MDGL News Today HALO News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IONS) was last updated on 12/23/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ionis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ionis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
